news
TRβ receptor could be key to slowing prostate cancer
A thyroid hormone receptor may play a key role in prostate cancer growth, offering a potential new target for treating aggressive forms of the disease.
List view / Grid view
Prostate cancer
article
From data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
news
CDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
news
Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.
news
New AI model may enable more targeted prostate cancer treatment
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
news
NSD2’s role in driving prostate cancer development
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
news
Novel compound for targeted alpha therapy
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
news
Transforming disease diagnosis with new nanoparticles
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
news
Prostate cancer: delaying resistance to hormone therapy
Researchers have developed a new form of immunotherapy that could provide a longer life expectancy to men with prostate cancer.
news
Reprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
news
Proteogenomic signatures: metastatic prostate cancer risk
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
news
MUTYH variants implicated in a broader range of cancers
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
article
The great prostate debate: innovations in prostate cancer screening
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
article
New research discovers gene mutations linked to prostate cancer
A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of aggressive prostate cancer.
news
Unexpected neuronal molecule makes prostate cancer more aggressive
US researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer.
